non-small cell lung cancer
Conditions
Interventions
A: paclitaxel 120mg/m2 + carboplatin AUC 3, day1 and day15, q4w, 4 course
B: TS-1 80mg/m2 oral, day1 to 14, q3w, 1 year
Sponsors
Nagoya City University thoracic oncology study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) pathologically proven non-small cell lung cancer 2) completely resected by lobectomy or pneumonectomy (+ other resection) 3) pathological stage II or IIIA (IASCL ver.7) 4) no prior chemotherapy or radiotherapy 5) PS 0 or 1 6) age 20-75 7) adequate organ function .WBC>=3500/mm3<=12000/mm3 .neutrophil<=2000/mm3 .platelet<=100000/mm3 .AST,ALT within 2 times of upper limit .total bilirubin within 2 times of upper limit .SpO2>=95% .creatinin within upper limit .creatinin clearance>=60ml/min/body 8) possible to receive chemotherapy within 8 weeks after surgery 9) oral intake possible 10) written informed consent
Exclusion criteria
Exclusion criteria: 1) apparent interstitial pneumonitis or pulmonary fibrosis 2) uncontroled pleural effusion or ascitis 3) multiple lung cancer 4) concomittant malignanct 5) past history of radiotherapy or chemotherapy 6) active infection or uncontroled complication 7) past history of severe allergic reaction 8) Pregnant or expecting woman 9) other conditions not suitable for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year relapse free survival | — |
Countries
Japan
Contacts
Public ContactMotoki Yano
Nagoya City University Graduate school of Medical Sciences Department of Oncology, Immunology, and Surgery
Outcome results
None listed